Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Health state</td><td align="left">Definition</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">1</td><td align="left">1st-line chemotherapy, preprogressive disease</td></tr><tr><td align="left">2</td><td align="left">2nd-line chemotherapy, preprogressive disease</td></tr><tr><td align="left">3</td><td align="left">3rd-line or higher chemotherapy, preprogressive disease</td></tr><tr><td align="left">4</td><td align="left">Progressive disease (on or off chemotherapy)</td></tr><tr><td align="left">5</td><td align="left">After chemotherapy, pre progressive disease</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Sarcoma

tab1

Table 1

Table 1: Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study 

Table 1 | Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study 